Anti-tumoral immunity is accomplished in this setting both through innate mechanisms with dendritic and NK cell inflammatory activation and through adaptive mechanisms involving CD4+ and CD8+ responses following the release of tumor-associated antigens from infected and lysed tumor cells. Here, CD4 is linked to neoplasm.